Method for detecting inflammation
AssigneeBoehringer Ingelheim Pharmaceuticals, Inc.
InventorsRobert Rothlein, Steven D. Marlin
Life of this patent
Estimating the term…
Abstract
A method for the detection of the presence of inflammation in a patient by measuring the amount of circulating intercellular adhesion molecule (cICAM-1) in a sample of one or more bodily fluids of the patient and then comparing the amount of cICAM-1 in the sample to standards normal for the bodily fluid or fluids assayed. The amount of cICAM-1 can be measured using anti-ICAM-1 antibodies. Higher than normal amounts of cICAM-1 indicate the presence of inflammation.
Claims14
A method for detecting inflammation in a patient which comprises the steps of contacting a sample of one or more body fluids of a patient with an antibody which specifically binds to circulating intercellular adhesion molecule 1, cICAM-1, to determine the amount of cICAM-1 present in said sample, and comparing the amount of cICAM-1 present in said sample to the amount of cICAM-1 present in standard samples obtained form normal individuals, wherein an elevated amount of cICAM-1 present in said sample is indicative of inflammation in said patient.
A method for the detection of inflammation in a patient which comprises the steps of:
- (a) contacting a sample of one or more bodily fluids of the patient, with an immobilized first antibody which specifically binds cICAM-1 and labelled second antibody which specifically binds cICAM-1;
- (b) determining an amount of bound labelled second antibody as a measure of the amount of cICAM-1 in the sample;
- (c) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for the one or more bodily fluids assayed
- wherein an elevated amount of cICAM-1 present in said sample is indicative of inflammation in said patient.
A method for the detection of inflammation in a patient which comprises the steps of:
- (a) contacting a sample of one or more bodily fluids of the patient with an immobilized first antibody which specifically binds cICAM-1, the immobilized first antibody being insoluble in the sample, to form a first insoluble complex of cICAM-1 and the immobilized first antibody;
- (b) incubating the first insoluble complex with a soluble labelled second antibody which specifically binds cICAM-1, to form a final insoluble complex of the labelled second antibody, cICAM-1, and the immobilized first antibody;
- (c) separating the final insoluble complex from the sample and any uncomplexed soluble labelled second antibody;
- (d) determining either an amount of label associated with the final insoluble complex or an amount of uncomplexed label, as a measure of the amount of cICAM-1 in the sample;
- (e) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for the one or more bodily fluids
- wherein an elevated amount of cICAM-1 present in said sample is indicative of inflammation in said patient.
A method for the detection of rheumatoid arthritis in a patient suspected of suffering from rheumatoid arthritis, which comprises the steps of:
- (a) contacting a sample of synovial fluid from the patient, with an immobilized first antibody which specifically binds cICAM-1, the immobilized first antibody being insoluble in the sample, to form a first insoluble complex of cICAM-1 and the immobilized first antibody;
- (b) contacting the first insoluble complex with a soluble labeled second antibody with specifically binds cICAM-1, to form a final insoluble complex of the labelled second antibody, cICAM-1 and the immobilized first antibody;
- (c) separating the final insoluble complex from the sample and any uncomplexed soluble labelled second antibody;
- (d) determining either an amount of label associated with the final insoluble complex or an amount of uncomplexed label, as a measure of the amount of cICAM-1 in the sample;
- (e) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for synovial fluid
- wherein an elevated amount of cICAM-1 present in said sample is indicative of rheumatoid arthritis in said patient.
A method for the detection of inflammation in a patient which comprises the steps of:
- (a) incubating a sample of one or more bodily fluids from the patient, with a soluble labelled second antibody which specifically binds cICAM-1, to form a soluble complex of cICAM-1 and the labelled second antibody;
- (b) incubating the soluble complex of (a) with an immobilized first antibody which specifically binds cICAM-1, the immobilized first antibody being insoluble in the sample, to form a final insoluble complex of the labelled second antibody, cICAM-1 and the immobilized first antibody;
- (c) separating the final insoluble complex from the sample and any uncomplexed soluble labelled second antibody;
- (d) determining either an amount of label associated with the final insoluble complex or an amount of uncomplexed label, as a measure of the amount of cICAM-1 in the sample;
- (e) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for the one or more bodily fluids
- wherein an elevated amount of cICAM-1 present in said sample is indicative of inflammation in said patient.
A method for the detection of inflammation in a patient which comprises the steps of:
- (a) incubating a sample of one or more bodily fluids from the patient, with (i) an immobilized first antibody which specifically binds cICAM-1, the immobilized first antibody being insoluble in the sample;
- and (ii) a soluble labelled second antibody which specifically binds cICAM-1, to form a final insoluble complex of the labelled second antibody, cICAM-1 and the immobilized first antibody;
- (b) separating the final insoluble complex from the sample and any uncomplexed soluble labelled second antibody;
- (c) determining either an amount of label associated with the final insoluble complex or an amount of uncomplexed label, as a measure of the amount of cICAM-1 in the sample;
- (d) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for the one or more bodily fluids
- wherein an elevated amount of cICAM-1 present in said sample is indicative of inflammation in said patient.
Dependencies are inferred from the claim text.